Gruss & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Gruss & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$511K	Buy	4,000 +500	+14%	+$62.4K	1.19%	16
2025 Q4	$427K	Sell	3,500 -500	-13%	-$57.3K	0.94%	19
2025 Q3	$401K	Buy	+4,000	New	+$360K	1.04%	16
2024 Q2	–	Sell	-6,000	Closed	-$569K	–	22
2024 Q1	$569K	Buy	+6,000	New	+$557K	3.14%	13
2016 Q4	–	Sell	-4,000	Closed	-$265K	–	47
2016 Q3	$265K	Hold	4,000	–	–	0.33%	30
2016 Q2	$216K	Hold	4,000	–	–	0.26%	31
2016 Q1	$207K	Sell	4,000 -4,000	-50%	-$208K	0.28%	32
2015 Q4	$561K	Hold	8,000	–	–	0.75%	29
2015 Q3	$498K	Sell	8,000 -8,500	-52%	-$670K	0.78%	24
2015 Q2	$1.39M	Buy	+16,500	New	+$1.28M	1.21%	23

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Gruss & Co's XBI Position: Q1 2026 in Review

Gruss & Co increased its State Street SPDR S&P Biotech ETF (XBI) stake by 14% in Q1 2026, buying an estimated $62.4K and bringing the position to 4,000 shares worth $511K. The position accounts for 1.19% of the portfolio, ranked #16.

Gruss & Co first reported a position in XBI in Q2 2015 and has held it in 10 quarters since. The position peaked at $1.39M in Q2 2015. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Gruss & Co held 4,000 shares of State Street SPDR S&P Biotech ETF worth $511K as of Q1 2026.
Gruss & Co bought 500 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $62.4K.
State Street SPDR S&P Biotech ETF made up 1.19% of Gruss & Co's portfolio in Q1 2026, its #16 holding.
Gruss & Co first reported a position in State Street SPDR S&P Biotech ETF in Q2 2015 and has held it in 10 quarters since.
Gruss & Co's State Street SPDR S&P Biotech ETF position peaked at $1.39M in Q2 2015.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Gruss & Co's 13F filing for Q1 2026, filed 5 May 2026.